[go: up one dir, main page]

AU2018249796A1 - Antibody Fc variants for improving blood half-life - Google Patents

Antibody Fc variants for improving blood half-life Download PDF

Info

Publication number
AU2018249796A1
AU2018249796A1 AU2018249796A AU2018249796A AU2018249796A1 AU 2018249796 A1 AU2018249796 A1 AU 2018249796A1 AU 2018249796 A AU2018249796 A AU 2018249796A AU 2018249796 A AU2018249796 A AU 2018249796A AU 2018249796 A1 AU2018249796 A1 AU 2018249796A1
Authority
AU
Australia
Prior art keywords
antibody
present
variants
life
improving blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2018249796A
Other versions
AU2018249796B2 (en
Inventor
So Young Choi
Sang Taek Jung
Su Jin Kim
Sanghwan KO
Soo Han Lee
Tae Gyu Lee
Ju Hyeon Lim
Jong Shik Park
So Ra Park
Myung Ho Sohn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kookmin University
Osong Medical Innovation Foundation
Original Assignee
Kookmin University
Osong Medical Innovation Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020170045142A external-priority patent/KR101913743B1/en
Priority claimed from KR1020170047822A external-priority patent/KR101792191B1/en
Priority claimed from KR1020170047821A external-priority patent/KR101792205B1/en
Application filed by Kookmin University, Osong Medical Innovation Foundation filed Critical Kookmin University
Publication of AU2018249796A1 publication Critical patent/AU2018249796A1/en
Application granted granted Critical
Publication of AU2018249796B2 publication Critical patent/AU2018249796B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to: a polypeptide comprising an Fc variant in which a part of the amino acid sequence of a human antibody Fc domain is substituted with a different amino acid sequence; or an antibody comprising the same. The Fc variant of the present invention can have a use in a wide range of antibodies and Fc fusion constructs. In one aspect, the antibodies or the Fc fusion constructs of the present invention are reagents for treatment, diagnosis or research and, preferably, reagents for treatment. The Fc variant of the present invention can maximize
AU2018249796A 2017-04-07 2018-04-06 Antibody Fc variants for improving blood half-life Active AU2018249796B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
KR10-2017-0045142 2017-04-07
KR1020170045142A KR101913743B1 (en) 2017-04-07 2017-04-07 Antibody Fc variants for Prolonged Serum Half-Life
KR1020170047822A KR101792191B1 (en) 2017-04-13 2017-04-13 Antibody Fc variants for Extended Serum Half-life
KR10-2017-0047822 2017-04-13
KR10-2017-0047821 2017-04-13
KR1020170047821A KR101792205B1 (en) 2017-04-13 2017-04-13 Antibody Fc variants for Prolonged Serum Persistence
PCT/KR2018/004104 WO2018186717A1 (en) 2017-04-07 2018-04-06 Antibody fc variants for improving blood half-life

Publications (2)

Publication Number Publication Date
AU2018249796A1 true AU2018249796A1 (en) 2019-11-21
AU2018249796B2 AU2018249796B2 (en) 2021-03-11

Family

ID=63712590

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018249796A Active AU2018249796B2 (en) 2017-04-07 2018-04-06 Antibody Fc variants for improving blood half-life

Country Status (7)

Country Link
US (2) US11492415B2 (en)
EP (2) EP3608339B1 (en)
JP (3) JP7264381B2 (en)
CN (1) CN110691796B (en)
AU (1) AU2018249796B2 (en)
CA (2) CA3059199C (en)
WO (1) WO2018186717A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3608339B1 (en) * 2017-04-07 2024-10-30 Kookmin University Industry Academy Cooperation Foundation Antibody fc variants for improving blood half-life
TWI869528B (en) 2020-01-13 2025-01-11 美商威特拉公司 Antibody molecules to c5ar1 and uses thereof
WO2021154046A1 (en) * 2020-01-29 2021-08-05 고려대학교 산학협력단 Ph-sensitive fc variant
WO2021190631A1 (en) * 2020-03-27 2021-09-30 泷搌（上海）生物科技有限公司 Method for displaying bispecific antibody on surface of mammalian cell and vector
TW202214703A (en) * 2020-07-10 2022-04-16 大陸商上海濟煜醫藥科技有限公司 An anti-ige engineered antibody and the use thereof
JP2023552456A (en) 2020-12-07 2023-12-15 インベテックス インコーポレイテッド Compositions and methods of use thereof for increasing the half-life of therapeutic agents in domestic animals
EP4277931A1 (en) 2021-01-13 2023-11-22 Visterra, Inc. Humanized complement 5a receptor 1 antibodies and methods of use thereof
CA3233084A1 (en) * 2021-09-24 2023-03-30 Bionsystems Inc Fusion protein dimer comprising pd-1 and il-21, and use thereof
CN116143932B (en) * 2022-12-07 2025-02-11 南开大学 An antibody or antigen-binding fragment thereof and Fc variant against IgE
WO2024186690A2 (en) * 2023-03-03 2024-09-12 Enosi Therapeutics Corporation Oligo-trap fusion proteins (ofps) and uses thereof
WO2025014774A1 (en) 2023-07-07 2025-01-16 Viridian Therapeutics, Inc. Methods of treating active and chronic thyroid eye disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2545603A1 (en) * 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
CN101189028B (en) * 2004-07-12 2013-05-29 马克罗基因公司 Identification and engineering of antibodies with variant Fc regions and methods of using the same
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
JP2008539753A (en) * 2005-05-09 2008-11-20 グリクアート バイオテクノロジー アクチェンゲゼルシャフト Antigen binding molecule having modified FC region and altered binding to FC receptor
EP2233500A1 (en) * 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
TWI667346B (en) * 2010-03-30 2019-08-01 中外製藥股份有限公司 Antibodies with modified affinity to fcrn that promote antigen clearance
WO2015158867A1 (en) * 2014-04-16 2015-10-22 Ucb Biopharma Sprl Multimeric fc proteins
AU2015365168B2 (en) * 2014-12-19 2021-08-05 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use
KR101792191B1 (en) 2017-04-13 2017-10-31 재단법인 오송첨단의료산업진흥재단 Antibody Fc variants for Extended Serum Half-life
EP3608339B1 (en) * 2017-04-07 2024-10-30 Kookmin University Industry Academy Cooperation Foundation Antibody fc variants for improving blood half-life
KR101792205B1 (en) * 2017-04-13 2017-10-31 재단법인 오송첨단의료산업진흥재단 Antibody Fc variants for Prolonged Serum Persistence

Also Published As

Publication number Publication date
US20230061390A1 (en) 2023-03-02
JP2021065242A (en) 2021-04-30
JP2022159401A (en) 2022-10-17
CA3120566C (en) 2023-12-12
JP7264381B2 (en) 2023-04-25
JP7533898B2 (en) 2024-08-14
JP7264383B2 (en) 2023-04-25
CN110691796B (en) 2024-05-07
US11492415B2 (en) 2022-11-08
CA3059199A1 (en) 2018-10-11
CN110691796A (en) 2020-01-14
EP3608339A1 (en) 2020-02-12
JP2020516310A (en) 2020-06-11
EP3608339A4 (en) 2020-12-23
EP4342541A3 (en) 2024-07-03
EP3608339C0 (en) 2024-10-30
CA3120566A1 (en) 2018-10-11
CA3059199C (en) 2023-02-21
AU2018249796B2 (en) 2021-03-11
EP3608339B1 (en) 2024-10-30
EP4342541A2 (en) 2024-03-27
WO2018186717A1 (en) 2018-10-11
US20200223938A1 (en) 2020-07-16

Similar Documents

Publication Publication Date Title
AU2018249796A1 (en) Antibody Fc variants for improving blood half-life
SA523442262B1 (en) CD3 Binding Antibodies
PH12021550802A1 (en) Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
MX2020009774A (en) Antibodies against signal-regulatory protein alpha and methods of use.
MX2024005027A (en) Cd3 binding antibodies.
EA201891435A1 (en) HUMANIZED MONOCLONAL ANTIBODIES, MONOCLONAL ANTIBODIES MOUSE OR CHEMERIC MONOCLONAL ANTIBODIES AGAINST CD47
CL2019001000A1 (en) Heterodimeric fc fusion proteins il15 / il15ralpha
WO2018187613A3 (en) Anti-icos agonist antibodies and uses thereof
PE20181054A1 (en) HUMANIZED ANTI-CD19 ANTIBODIES AND METHODS OF USE
BR112016011025A2 (en) antibody polypeptides and their uses
EA201992570A1 (en) COMPOSITIONS BASED ON HUMAN ANTIBODIES TO RANKL, AND ALSO WAYS OF THEIR APPLICATION
WO2017075432A3 (en) Anti-siglec-9 antibodies and methods of use thereof
EA201391761A1 (en) ANTI-ALPHA-SINUCLAIN-BINDING MOLECULES
EA201490745A1 (en) POLYPEPTIDES OF ANTIBODIES THAT CAUSE ANTAGONISM CD40L
EA201391753A1 (en) DOMAINS CONNECTING WITH DEIMMUNIZED SERUM AND THEIR APPLICATION TO INCREASE THE TIME OF HALF-DURATION
EA201590138A1 (en) OPTIMIZATION OF ANTIBODIES THAT BIND THE ACTIVATION GENE OF LYMPHOCYTES 3 (LAG-3) AND THEIR USE
EP2352523A4 (en) IMPROVED ANTI-CD19 ANTIBODIES
MX2019000529A (en) Brain delivery protein.
EA201390820A1 (en) Fusion protein against cancer
EA202091239A1 (en) FUSION PROTEIN BASED ON A THERAPEUTIC ENZYME WITH A NEW STRUCTURE AND ITS APPLICATION
SG10201903142RA (en) Serpin fusion polypeptides and methods of use thereof
EA201790341A1 (en) ANTI-CK8 ANTIBODIES FOR USE IN TREATMENT OF CANCER
EA201391546A1 (en) ANTI-TRACT FUSE PROTEIN
MX2023011862A (en) Gucy2c binding polypeptide and uses thereof.
PL401502A1 (en) Epitope and its application

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)